Medicine and Dentistry
Elderly Patient
100%
Temozolomide
100%
Primary Central Nervous System Lymphoma
66%
Lymphoma
33%
Toxicity
33%
Overall Survival
33%
Progression Free Survival
33%
Combination Therapy
33%
Maintenance Therapy
33%
Vincristine
33%
Methotrexate
33%
Rituximab
33%
Procarbazine
33%
Patient
33%
Pharmacology, Toxicology and Pharmaceutical Science
Temozolomide
100%
Primary Central Nervous System Lymphoma
66%
Overall Survival
33%
Progression Free Survival
33%
Toxicity
33%
Vincristine
33%
Lymphoma
33%
Methotrexate
33%
Rituximab
33%
Procarbazine
33%
Neuroscience
Temozolomide
100%
Primary Central Nervous System Lymphoma
66%
Lymphoma
33%
Vincristine
33%
Methotrexate
33%
Rituximab
33%
Procarbazine
33%
Biochemistry, Genetics and Molecular Biology
Overall Survival
33%
Methotrexate
33%
Progression Free Survival
33%
Rituximab
33%
Procarbazine
33%
Immunology and Microbiology
Progression Free Survival
33%
Overall Survival
33%
Methotrexate
33%
Rituximab
33%